| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6185486 | Gynecologic Oncology | 2013 | 7 Pages |
Abstract
Age, histology, and extent of residual disease were predictors of OS in stage III patients treated with IP chemotherapy following optimal cytoreduction. Patients with no residual disease following primary surgery that are treated with adjuvant platinum based IP chemotherapy have survival measures that exceed any rates previously seen in this population.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Lisa M. Landrum, James Java, Cara A. Mathews, Grainger S. Jr., Larry J. Copeland, Deborah K. Armstrong, Joan L. Walker,